| 1 |
32598478 | Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor. | 2020 Nov 26 |
1 |
| 2 |
29318783 | TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia. | 2018 Jul |
2 |
| 3 |
28381659 | A strategy to improve the success rate of CNS drug development: TAK-063, a novel PDE10A inhibitor, as a case study. | 2017 |
1 |
| 4 |
29103081 | A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events. | 2017 Dec |
2 |
| 5 |
27423256 | A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor. | 2016 Nov 1 |
5 |
| 6 |
27572830 | A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. | 2016 Oct |
1 |